Rapid Expansion Cresilon has recently expanded its manufacturing facilities to 55,000 square feet in Brooklyn, indicating strong growth and increased capacity, presenting opportunities to supply raw materials, manufacturing equipment, or logistical services.

Innovative Product Launch The launch and nationwide rollout of TRAUMAGEL, a cutting-edge hemostatic product, opens avenues for sales in hospitals, trauma centers, emergency response units, and military medical supplies.

Strong Funding Background With significant venture capital funding of $130 million and recent growth, Cresilon is well-positioned to invest in new product lines and expand distribution channels, creating opportunities for strategic partnerships and infrastructure support.

Market Recognition Being named one of the World's Most Innovative Companies in 2024 enhances Cresilon’s credibility, making it a promising partner for distributors and healthcare providers seeking advanced and proven hemostatic solutions.

Active Industry Engagement Participation in prominent events like the ATLS Global Symposium and clinical case presentations showcase Cresilon’s active presence in trauma and emergency medicine markets, highlighting potential sales channels within medical professionals and institutions focused on trauma care innovations.